Daiichi Sankyo hits phase III endpoint for prasugrel, inks deal with Gustave Roussy July 28, 2020 By David Ho and Gina Lee HONG KONG – Tokyo-based Daiichi Sankyo Co. Ltd. has hit its goals in a phase III study testing the use of prasugrel hydrochloride in thrombotic stroke patients.Read More
